Used in advanced pharmaceutical formulations for targeted cardiovascular therapy, particularly in sustained-release systems. This derivative of carvedilol, featuring a 9H-carbazol-4-yloxy group attached via a 2-hydroxypropyl linker, enhances bioavailability and tissue selectivity of carvedilol, improving treatment efficacy in chronic heart failure and hypertension. The carbazole moiety increases lipophilicity, facilitating better cell membrane penetration, and may provide antioxidant properties to protect cells from oxidative damage. Shows potential for reduced dosing frequency and minimized side effects due to controlled delivery and improved pharmacokinetic profile, including enhanced blood stability and prolonged action. Investigated for use in transdermal and oral extended-release preparations.